Clinical Infectious Diseases · 2021 · 31 citations · 17 references
Veterinary MedicineImmunologyInfectious DiseasesClinical ImmunologyEarly DetectionPublic Health SurveillanceAntibody ScreeningDiagnostic ImmunologyInfectious Disease ScreeningSerological DiagnosticsViral DiagnosticsAntibody Detection TestsCoronavirus DiagnosticsSars-cov-2 InfectionSensitivitySevere Acute Respiratory SyndromeTravel History AssessmentViral Antigen DetectionViral Serology Screening
BACKGROUND: With limited severe acute respiratory syndrome coronavirus (SARS-CoV-2) testing capacity in the United States at the start of the epidemic (January-March 2020), testing was focused on symptomatic patients with a travel history throughout February, obscuring the picture of SARS-CoV-2 seeding and community transmission. We sought to identify individuals with SARS-CoV-2 antibodies in the early weeks of the US epidemic. METHODS: All of Us study participants in all 50 US states provided blood specimens during study visits from 2 January to 18 March 2020. Participants were considered seropositive if they tested positive for SARS-CoV-2 immunoglobulin G (IgG) antibodies with the Abbott Architect SARS-CoV-2 IgG enzyme-linked immunosorbent assay (ELISA) and the EUROIMMUN SARS-CoV-2 ELISA in a sequential testing algorithm. The sensitivity and specificity of these ELISAs and the net sensitivity and specificity of the sequential testing algorithm were estimated, along with 95% confidence intervals (CIs). RESULTS: The estimated sensitivities of the Abbott and EUROIMMUN assays were 100% (107 of 107 [95% CI: 96.6%-100%]) and 90.7% (97 of 107 [83.5%-95.4%]), respectively, and the estimated specificities were 99.5% (995 of 1000 [98.8%-99.8%]) and 99.7% (997 of 1000 [99.1%-99.9%]), respectively. The net sensitivity and specificity of our sequential testing algorithm were 90.7% (97 of 107 [95% CI: 83.5%-95.4%]) and 100.0% (1000 of 1000 [99.6%-100%]), respectively. Of the 24 079 study participants with blood specimens from 2 January to 18 March 2020, 9 were seropositive, 7 before the first confirmed case in the states of Illinois, Massachusetts, Wisconsin, Pennsylvania, and Mississippi. CONCLUSIONS: Our findings identified SARS-CoV-2 infections weeks before the first recognized cases in 5 US states.
17
Kelvin Kai‐Wang To, Owen Tak-Yin Tsang, Wai-Shing Leung et al. · The Lancet Infectious Diseases · 2020 · 3.4K citations · Full text
The “All of Us” Research Program
New England Journal of Medicine · 2019 · 2.3K citations · Full text
COVID-19 and Racial/Ethnic Disparities
Monica Webb Hooper, Anna María Nápoles, Eliseo J. Pérez‐Stable · JAMA · 2020 · 2.2K citations · Full text
Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)
Li Guo, Lili Ren, Siyuan Yang et al. · Clinical Infectious Diseases · 2020 · 1.7K citations · Full text